Cargando…
A Novel UC Exclusion Diet and Antibiotics for Treatment of Mild to Moderate Pediatric Ulcerative Colitis: A Prospective Open-Label Pilot Study
Background: As the microbiome plays an important role in instigating inflammation in ulcerative colitis (UC), strategies targeting the microbiome may offer an alternative therapeutic approach. The goal of the pilot trial was to evaluate the potential efficacy and feasibility of a novel UC exclusion...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8622458/ https://www.ncbi.nlm.nih.gov/pubmed/34835992 http://dx.doi.org/10.3390/nu13113736 |
_version_ | 1784605698530738176 |
---|---|
author | Sarbagili-Shabat, Chen Albenberg, Lindsey Van Limbergen, Johan Pressman, Naomi Otley, Anthony Yaakov, Michal Wine, Eytan Weiner, Dror Levine, Arie |
author_facet | Sarbagili-Shabat, Chen Albenberg, Lindsey Van Limbergen, Johan Pressman, Naomi Otley, Anthony Yaakov, Michal Wine, Eytan Weiner, Dror Levine, Arie |
author_sort | Sarbagili-Shabat, Chen |
collection | PubMed |
description | Background: As the microbiome plays an important role in instigating inflammation in ulcerative colitis (UC), strategies targeting the microbiome may offer an alternative therapeutic approach. The goal of the pilot trial was to evaluate the potential efficacy and feasibility of a novel UC exclusion diet (UCED) for clinical remission, as well as the potential of sequential antibiotics for diet-refractory patients to achieve remission without steroids. Methods: This was a prospective, single-arm, multicenter, open-label pilot study in patients aged 8–19, with pediatric UC activity index (PUCAI) scores >10 on stable maintenance therapy. Patients failing to enter remission (PUCAI < 10) on the diet could receive a 14-day course of amoxycillin, metronidazole and doxycycline (AMD), and were re-assessed on day 21. The primary endpoint was intention-to-treat (ITT) remission at week 6, with UCED as the only intervention. Results: Twenty-four UCED treatment courses were given to 23 eligible children (mean age: 15.3 ± 2.9 years). The median PUCAI decreased from 35 (30–40) at baseline to 12.5 (5–30) at week 6 (p = 0.001). Clinical remission with UCED alone was achieved in 9/24 (37.5%). The median fecal calprotectin declined from 818 (630.0–1880.0) μg/g at baseline to 592.0 (140.7–1555.0) μg/g at week 6 (p > 0.05). Eight patients received treatment with antibiotics after failing on the diet; 4/8 (50.0%) subsequently entered remission 3 weeks later. Conclusion: The UCED appears to be effective and feasible for the induction of remission in children with mild to moderate UC. The sequential use of UCED followed by antibiotic therapy needs to be evaluated as a microbiome-targeted, steroid-sparing strategy. |
format | Online Article Text |
id | pubmed-8622458 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86224582021-11-27 A Novel UC Exclusion Diet and Antibiotics for Treatment of Mild to Moderate Pediatric Ulcerative Colitis: A Prospective Open-Label Pilot Study Sarbagili-Shabat, Chen Albenberg, Lindsey Van Limbergen, Johan Pressman, Naomi Otley, Anthony Yaakov, Michal Wine, Eytan Weiner, Dror Levine, Arie Nutrients Article Background: As the microbiome plays an important role in instigating inflammation in ulcerative colitis (UC), strategies targeting the microbiome may offer an alternative therapeutic approach. The goal of the pilot trial was to evaluate the potential efficacy and feasibility of a novel UC exclusion diet (UCED) for clinical remission, as well as the potential of sequential antibiotics for diet-refractory patients to achieve remission without steroids. Methods: This was a prospective, single-arm, multicenter, open-label pilot study in patients aged 8–19, with pediatric UC activity index (PUCAI) scores >10 on stable maintenance therapy. Patients failing to enter remission (PUCAI < 10) on the diet could receive a 14-day course of amoxycillin, metronidazole and doxycycline (AMD), and were re-assessed on day 21. The primary endpoint was intention-to-treat (ITT) remission at week 6, with UCED as the only intervention. Results: Twenty-four UCED treatment courses were given to 23 eligible children (mean age: 15.3 ± 2.9 years). The median PUCAI decreased from 35 (30–40) at baseline to 12.5 (5–30) at week 6 (p = 0.001). Clinical remission with UCED alone was achieved in 9/24 (37.5%). The median fecal calprotectin declined from 818 (630.0–1880.0) μg/g at baseline to 592.0 (140.7–1555.0) μg/g at week 6 (p > 0.05). Eight patients received treatment with antibiotics after failing on the diet; 4/8 (50.0%) subsequently entered remission 3 weeks later. Conclusion: The UCED appears to be effective and feasible for the induction of remission in children with mild to moderate UC. The sequential use of UCED followed by antibiotic therapy needs to be evaluated as a microbiome-targeted, steroid-sparing strategy. MDPI 2021-10-23 /pmc/articles/PMC8622458/ /pubmed/34835992 http://dx.doi.org/10.3390/nu13113736 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sarbagili-Shabat, Chen Albenberg, Lindsey Van Limbergen, Johan Pressman, Naomi Otley, Anthony Yaakov, Michal Wine, Eytan Weiner, Dror Levine, Arie A Novel UC Exclusion Diet and Antibiotics for Treatment of Mild to Moderate Pediatric Ulcerative Colitis: A Prospective Open-Label Pilot Study |
title | A Novel UC Exclusion Diet and Antibiotics for Treatment of Mild to Moderate Pediatric Ulcerative Colitis: A Prospective Open-Label Pilot Study |
title_full | A Novel UC Exclusion Diet and Antibiotics for Treatment of Mild to Moderate Pediatric Ulcerative Colitis: A Prospective Open-Label Pilot Study |
title_fullStr | A Novel UC Exclusion Diet and Antibiotics for Treatment of Mild to Moderate Pediatric Ulcerative Colitis: A Prospective Open-Label Pilot Study |
title_full_unstemmed | A Novel UC Exclusion Diet and Antibiotics for Treatment of Mild to Moderate Pediatric Ulcerative Colitis: A Prospective Open-Label Pilot Study |
title_short | A Novel UC Exclusion Diet and Antibiotics for Treatment of Mild to Moderate Pediatric Ulcerative Colitis: A Prospective Open-Label Pilot Study |
title_sort | novel uc exclusion diet and antibiotics for treatment of mild to moderate pediatric ulcerative colitis: a prospective open-label pilot study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8622458/ https://www.ncbi.nlm.nih.gov/pubmed/34835992 http://dx.doi.org/10.3390/nu13113736 |
work_keys_str_mv | AT sarbagilishabatchen anovelucexclusiondietandantibioticsfortreatmentofmildtomoderatepediatriculcerativecolitisaprospectiveopenlabelpilotstudy AT albenberglindsey anovelucexclusiondietandantibioticsfortreatmentofmildtomoderatepediatriculcerativecolitisaprospectiveopenlabelpilotstudy AT vanlimbergenjohan anovelucexclusiondietandantibioticsfortreatmentofmildtomoderatepediatriculcerativecolitisaprospectiveopenlabelpilotstudy AT pressmannaomi anovelucexclusiondietandantibioticsfortreatmentofmildtomoderatepediatriculcerativecolitisaprospectiveopenlabelpilotstudy AT otleyanthony anovelucexclusiondietandantibioticsfortreatmentofmildtomoderatepediatriculcerativecolitisaprospectiveopenlabelpilotstudy AT yaakovmichal anovelucexclusiondietandantibioticsfortreatmentofmildtomoderatepediatriculcerativecolitisaprospectiveopenlabelpilotstudy AT wineeytan anovelucexclusiondietandantibioticsfortreatmentofmildtomoderatepediatriculcerativecolitisaprospectiveopenlabelpilotstudy AT weinerdror anovelucexclusiondietandantibioticsfortreatmentofmildtomoderatepediatriculcerativecolitisaprospectiveopenlabelpilotstudy AT levinearie anovelucexclusiondietandantibioticsfortreatmentofmildtomoderatepediatriculcerativecolitisaprospectiveopenlabelpilotstudy AT sarbagilishabatchen novelucexclusiondietandantibioticsfortreatmentofmildtomoderatepediatriculcerativecolitisaprospectiveopenlabelpilotstudy AT albenberglindsey novelucexclusiondietandantibioticsfortreatmentofmildtomoderatepediatriculcerativecolitisaprospectiveopenlabelpilotstudy AT vanlimbergenjohan novelucexclusiondietandantibioticsfortreatmentofmildtomoderatepediatriculcerativecolitisaprospectiveopenlabelpilotstudy AT pressmannaomi novelucexclusiondietandantibioticsfortreatmentofmildtomoderatepediatriculcerativecolitisaprospectiveopenlabelpilotstudy AT otleyanthony novelucexclusiondietandantibioticsfortreatmentofmildtomoderatepediatriculcerativecolitisaprospectiveopenlabelpilotstudy AT yaakovmichal novelucexclusiondietandantibioticsfortreatmentofmildtomoderatepediatriculcerativecolitisaprospectiveopenlabelpilotstudy AT wineeytan novelucexclusiondietandantibioticsfortreatmentofmildtomoderatepediatriculcerativecolitisaprospectiveopenlabelpilotstudy AT weinerdror novelucexclusiondietandantibioticsfortreatmentofmildtomoderatepediatriculcerativecolitisaprospectiveopenlabelpilotstudy AT levinearie novelucexclusiondietandantibioticsfortreatmentofmildtomoderatepediatriculcerativecolitisaprospectiveopenlabelpilotstudy |